Cargando…

Systemic Amyloidosis in England: an epidemiological study

Epidemiological studies of systemic amyloidosis are scarce and the burden of disease in England has not previously been estimated. In 1999, the National Health Service commissioned the National Amyloidosis Centre (NAC) to provide a national clinical service for all patients with amyloidosis. Data fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pinney, Jennifer H, Smith, Colette J, Taube, Jessi B, Lachmann, Helen J, Venner, Christopher P, Gibbs, Simon D J, Dungu, Jason, Banypersad, Sanjay M, Wechalekar, Ashutosh D, Whelan, Carol J, Hawkins, Philip N, Gillmore, Julian D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Haematological Malignancy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4296340/ https://www.ncbi.nlm.nih.gov/pubmed/23480608 http://dx.doi.org/10.1111/bjh.12286

Ejemplares similares

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

Senile Systemic Amyloidosis: Clinical Features at Presentation and Outcome
por: Pinney, Jennifer H., et al.
Publicado: (2013)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

Updates in Cardiac Amyloidosis: A Review
por: Banypersad, Sanjay M., et al.
Publicado: (2012)

OR14-001 – Tocilizumab in autoinflammation and AA amyloidosis
por: Lane, T, et al.
Publicado: (2013)

T1 mapping and survival in systemic light-chain amyloidosis
por: Banypersad, Sanjay M., et al.
Publicado: (2015)

DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience
por: Hutt, David, et al.
Publicado: (2015)

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients
por: Levin, Nancy, et al.
Publicado: (2016)

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia
por: Stuart, Robert K, et al.
Publicado: (2015)

Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond–Blackfan anaemia
por: Sjögren, Sara E., et al.
Publicado: (2015)

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results
por: Richardson, Paul G., et al.
Publicado: (2018)

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma
por: Chen, Christine, et al.
Publicado: (2009)

A novel mass spectrometry method to identify the serum monoclonal light chain component in systemic light chain amyloidosis
por: Sharpley, Faye A., et al.
Publicado: (2019)

Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review
por: van Westrhenen, Anouk, et al.
Publicado: (2018)

Early‐stage Hodgkin lymphoma in the modern era: simulation modelling to delineate long‐term patient outcomes
por: Parsons, Susan K., et al.
Publicado: (2018)

Patient and physician preferences for first‐line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom
por: Bröckelmann, Paul J., et al.
Publicado: (2018)

Clinical activity of carfilzomib correlates with inhibition of multiple proteasome subunits: application of a novel pharmacodynamic assay
por: Lee, Susan J., et al.
Publicado: (2016)

Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study
por: Pettengell, Ruth, et al.
Publicado: (2008)

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study
por: Royle, Kara‐Louise, et al.
Publicado: (2018)

Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome
por: Toft‐Petersen, Marie, et al.
Publicado: (2016)

Differences in incidence and trends of haematological malignancies in Japan and the United States
por: Chihara, Dai, et al.
Publicado: (2014)

Aberrant splicing of genes involved in haemoglobin synthesis and impaired terminal erythroid maturation in SF3B1 mutated refractory anaemia with ring sideroblasts
por: Conte, Simona, et al.
Publicado: (2015)

Diagnostic value of fat aspirates for amyloidosis in 950 patients
por: Gilbertson, JA, et al.
Publicado: (2015)

Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study
por: Dimopoulos, Meletios A., et al.
Publicado: (2017)

Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines
por: Leupin, Nicolas, et al.
Publicado: (2006)

Economic impact of genomic diagnostics for intermediate‐risk acute myeloid leukaemia
por: Cressman, Sonya, et al.
Publicado: (2016)

Lenalidomide plus rituximab (R(2)) in previously untreated marginal zone lymphoma: subgroup analysis and long‐term follow‐up of an open‐label phase 2 trial
por: Becnel, Melody R., et al.
Publicado: (2019)

Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response
por: Latifoltojar, Arash, et al.
Publicado: (2016)

The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long‐term follow‐up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open‐label, phase 3 trial
por: Cook, Gordon, et al.
Publicado: (2019)

Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model
por: Gassner, Franz J, et al.
Publicado: (2015)

Cardiac biomarkers are prognostic in systemic light chain amyloidosis with no cardiac involvement by standard criteria
por: Sharpley, Faye A., et al.
Publicado: (2020)

A 4‐gene expression score associated with high levels of Wilms Tumor‐1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia
por: Niavarani, Ahmadreza, et al.
Publicado: (2016)

The value of molecular stratification for CEBPA (DM) and NPM1 (MUT) FLT3 (WT) genotypes in older patients with acute myeloid leukaemia
por: Dickson, Glenda J., et al.
Publicado: (2015)

CSNK1A1 mutations and gene expression analysis in myelodysplastic syndromes with del(5q)
por: Bello, Erica, et al.
Publicado: (2015)

Ublituximab (TG‐1101), a novel glycoengineered anti‐CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial
por: Sharman, Jeff P., et al.
Publicado: (2016)

Timing of autologous stem cell transplantation from last chemotherapy affects lymphocyte collection and survival in non-Hodgkin lymphoma
por: Holtan, Shernan G, et al.
Publicado: (2006)

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis
por: Gupta, Neeraj, et al.
Publicado: (2016)

CXCR2 modulates bone marrow vascular repair and haematopoietic recovery post‐transplant
por: Hale, Sarah J. M., et al.
Publicado: (2015)

Longer‐term follow‐up and outcome by tumour cell proliferation rate (Ki‐67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL‐001(EMERGE) pivotal trial
por: Goy, Andre, et al.
Publicado: (2015)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bj8hv3ucakoifuafevvc87bqve